Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach?

J Pers Med · 2022 · PMC9324979 · PMID 35887631

Europe PMC DOI

hedged sentence

0.0810

closest p · 1.6× alpha

0.0810

boldest claim

The sentences

showed a trendp = 0.081so close (0.05 < p ≤ 0.1)

only showed a trend of worse median OS of those with p53 genomic deletions versus those with wild type TP53 alleles (2.1 versus 3.1 years; p = 0.081) [ 25 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.